Vlek A L M, van der Graaf Y, Spiering W, Visseren F L J
Julius Center for Health Sciences and Primary Care, Department of Epidemiology, University Medical Center Utrecht, Utrecht, The Netherlands.
J Hum Hypertens. 2008 May;22(5):358-65. doi: 10.1038/jhh.2008.5. Epub 2008 Feb 14.
Patients with hypertension and manifest vascular disease are at high risk for recurrent cardiovascular diseases. It is unknown if the metabolic syndrome further increases the risk in these patients. This study aims to quantify the effect of metabolic syndrome and type II diabetes on cardiovascular events in hypertensive patients with vascular disease. A total of 2,196 hypertensive patients with vascular disease (cerebrovascular disease (34%), coronary heart disease (50%), peripheral arterial disease (28%), abdominal aortic aneurysm (13%)) from the Second Manifestations of Arterial Disease study were followed for up to 10 years (mean 3.9 years) for death, stroke and myocardial infarction. Age and sex adjusted hazard ratios (HR) were calculated for hypertensive patients with metabolic syndrome but without diabetes (n=775) and for hypertensive patients with type II diabetes (n=381), compared to merely hypertensive patients (n=1,040). Forty-nine percent had metabolic syndrome (NCEP ATPIII definition) and 17% had type II diabetes. Metabolic syndrome predicted vascular death (HR 1.41, 95% confidence interval (CI) 1.01-1.98), stroke (HR 1.36, 95% CI 0.85-2.16) and myocardial infarction (HR 1.40, 95% CI 0.97-2.01). Type II diabetes accounted for even higher risks of vascular end points (HR 1.41-1.64). The effect of metabolic syndrome on future events could not be explained by the presence of type II diabetes. Even in high-risk patients with hypertension and vascular disease, presence of metabolic syndrome or type II diabetes identifies patients at high risk for future cardiovascular events. Identifying metabolic syndrome patients may direct therapy focusing on treatment of insulin resistance by reducing weight and increasing physical activity.
患有高血压且有明显血管疾病的患者发生心血管疾病复发的风险很高。目前尚不清楚代谢综合征是否会进一步增加这些患者的风险。本研究旨在量化代谢综合征和II型糖尿病对患有血管疾病的高血压患者心血管事件的影响。对来自动脉疾病二次表现研究的2196例患有血管疾病(脑血管疾病(34%)、冠心病(50%)、外周动脉疾病(28%)、腹主动脉瘤(13%))的高血压患者进行了长达10年(平均3.9年)的随访,观察其死亡、中风和心肌梗死情况。计算了患有代谢综合征但无糖尿病的高血压患者(n = 775)和患有II型糖尿病的高血压患者(n = 381)与单纯高血压患者(n = 1040)相比,经年龄和性别调整后的风险比(HR)。49%的患者患有代谢综合征(根据美国国家胆固醇教育计划成人治疗组第三次报告(NCEP ATPIII)定义),17%的患者患有II型糖尿病。代谢综合征可预测血管性死亡(HR 1.41,95%置信区间(CI)1.01 - 1.98)、中风(HR 1.36,95% CI 0.85 - 2.16)和心肌梗死(HR 1.40,95% CI 0.97 - 2.01)。II型糖尿病导致血管终点事件的风险更高(HR 1.41 - 1.64)。代谢综合征对未来事件的影响无法通过II型糖尿病的存在来解释。即使在患有高血压和血管疾病的高危患者中,代谢综合征或II型糖尿病的存在也表明患者未来发生心血管事件的风险很高。识别代谢综合征患者可能有助于指导治疗,通过减轻体重和增加体力活动来专注于胰岛素抵抗的治疗。